Hospital
Community Memorial Health System
Community Memorial Health System was paid $94.18M by Medicaid between Jan 2018 and Nov 2024, across 567 billing codes. Its largest line is 0761, — 10% of everything it billed.
33Billing provider infoCOMMUNITY MEMORIAL HEALTH SYSTEM
VENTURA, CA 93003
VENTURA, CA 93003
33aNPI1215903018assigned 02/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$94.18M
24GClaims3,030,251
24DCodes billed567
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#24 of 410
Median peer was paid$6.90M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 569,356 | $15.56M | |
| 2019 | 585,126 | $15.58M | |
| 2020 | 372,157 | $9.18M | |
| 2021 | 368,099 | $11.66M | |
| 2022 | 409,106 | $15.01M | |
| 2023 | 432,724 | $17.02M | |
| 2024incomplete | 293,683 | $10.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0761 | 10% | 335,103 | 254,749 | $9.47M | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 9.7% | 299,245 | 239,765 | $9.18M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.2% | 304,535 | 281,523 | $6.75M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 6.6% | 43,130 | 38,191 | $6.26M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.2% | 209,422 | 197,460 | $4.90M |
| 0360 | 3.9% | 26,059 | 13,833 | $3.63M | |
| 0450 | Emergency room services | 2.3% | 48,461 | 43,555 | $2.21M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 23,356 | 21,785 | $2.00M |
| 59425 | 2.0% | 25,324 | 16,235 | $1.87M | |
| L8699 | Prosthetic implant, not otherwise specified | 1.9% | 549 | 525 | $1.77M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 5,805 | 5,662 | $1.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.5% | 6,954 | 6,545 | $1.39M |
555 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,669 | $1.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 12,837 | $977K |
| 80053 | Comprehensive metabolic panel | <1% | 51,344 | $900K |
| 99283 | Emergency room visit (moderate) | <1% | 5,656 | $871K |
| 0760 | <1% | 20,501 | $858K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 15,069 | $843K |
| J3490 | Unclassified drugs | <1% | 20,119 | $824K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 8,544 | $818K |
| 87428 | <1% | 10,205 | $780K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,186 | $697K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 15,827 | $695K |
| 0510 | <1% | 23,463 | $680K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 13,247 | $674K |
| 99490 | Ccm add 20min | <1% | 33,548 | $666K |
| 99285 | Emergency room visit (most serious) | <1% | 3,699 | $663K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,736 | $654K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,778 | $646K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,509 | $644K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,779 | $623K |
| A4649 | Surgical supply; miscellaneous | <1% | 65,212 | $584K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,318 | $571K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,048 | $514K |
| 0710 | <1% | 13,049 | $498K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,703 | $456K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 7,242 | $455K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,702 | $452K |
| 97139 | <1% | 9,302 | $447K | |
| Z7500 | <1% | 12,911 | $436K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,703 | $408K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,251 | $392K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,241 | $390K |
| 87631 | <1% | 5,641 | $387K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,641 | $381K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,191 | $344K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,563 | $329K |
| Z7502 | <1% | 8,736 | $329K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,340 | $327K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,340 | $325K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 4,292 | $321K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,474 | $307K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,093 | $306K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,488 | $306K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,380 | $304K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,785 | $303K |
| 87507 | <1% | 661 | $298K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,259 | $288K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,762 | $284K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18,213 | $276K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,367 | $275K |
| 99460 | <1% | 5,001 | $269K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,196 | $268K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,080 | $268K |
| 76801 | <1% | 3,283 | $264K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,190 | $257K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,234 | $256K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 19,618 | $242K |
| Z1034 | <1% | 3,456 | $240K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,285 | $236K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,608 | $235K |
| 90686 | <1% | 17,301 | $212K | |
| 97802 | <1% | 2,403 | $205K | |
| 51798 | <1% | 3,726 | $202K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,838 | $202K |
| 93971 | <1% | 1,921 | $201K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 15,149 | $200K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,967 | $200K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,061 | $198K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,625 | $198K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,146 | $195K |
| 80061 | Lipid panel | <1% | 17,174 | $194K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,366 | $193K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 757 | $173K |
| 93975 | <1% | 726 | $170K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 26,786 | $169K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,595 | $167K |
| 99243 | <1% | 2,245 | $156K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,492 | $156K |
| 99242 | <1% | 2,896 | $155K | |
| 93458 | <1% | 202 | $155K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15,632 | $150K |
| 83690 | <1% | 23,526 | $150K | |
| G0378 | Hospital observation service, per hour | <1% | 576 | $149K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 978 | $149K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,334 | $148K |
| V5008 | Hearing screening | <1% | 3,574 | $141K |
| 73630 | <1% | 5,444 | $140K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,051 | $136K |
| 86003 | <1% | 1,024 | $135K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,129 | $135K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,249 | $134K |
| 73610 | <1% | 4,822 | $131K | |
| H0049 | Alcohol and/or drug screening | <1% | 5,439 | $129K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 320 | $126K |
| 76770 | <1% | 1,410 | $122K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,834 | $121K |
| 99462 | <1% | 3,958 | $120K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,374 | $120K |
| 59025 | Fetal non-stress test | <1% | 3,516 | $118K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 184 | $118K |
| 86850 | <1% | 3,641 | $117K | |
| 81025 | <1% | 26,295 | $112K | |
| 90670 | <1% | 12,133 | $111K | |
| Z9725 | <1% | 3,495 | $108K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,753 | $106K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 262 | $101K |
| 85027 | <1% | 17,263 | $97K | |
| 73130 | <1% | 3,542 | $97K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,851 | $97K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 306 | $96K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,302 | $94K |
| 62323 | <1% | 489 | $91K | |
| 90715 | <1% | 3,583 | $91K | |
| 84484 | <1% | 11,373 | $90K | |
| 73562 | <1% | 3,038 | $87K | |
| 73030 | <1% | 3,272 | $85K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 46,507 | $84K |
| 95886 | <1% | 1,045 | $83K | |
| 17110 | <1% | 795 | $83K | |
| 73110 | <1% | 2,987 | $82K | |
| 73564 | <1% | 3,459 | $81K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 251 | $80K |
| 99443 | <1% | 1,013 | $80K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 4,233 | $79K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,743 | $78K |
| 81002 | <1% | 31,238 | $78K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,919 | $76K |
| 88304 | <1% | 1,940 | $75K | |
| 84703 | <1% | 10,663 | $74K | |
| 99188 | <1% | 3,538 | $74K | |
| 73221 | <1% | 254 | $72K | |
| 0258 | <1% | 1,188 | $71K | |
| 72100 | <1% | 2,295 | $70K | |
| 0250 | <1% | 1,563 | $70K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,931 | $64K |
| 73502 | <1% | 2,041 | $64K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 832 | $63K |
| 95144 | <1% | 5,023 | $62K | |
| 70486 | <1% | 370 | $62K | |
| 88341 | <1% | 608 | $62K | |
| 97161 | <1% | 1,288 | $60K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,176 | $58K |
| 87077 | <1% | 7,277 | $57K | |
| 85018 | <1% | 45,716 | $57K | |
| Q3014 | Telehealth originating site facility fee | <1% | 6,992 | $56K |
| 83013 | <1% | 762 | $56K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,848 | $56K |
| 73080 | <1% | 1,757 | $55K | |
| 87186 | <1% | 6,365 | $54K | |
| 93970 | <1% | 316 | $52K | |
| 90633 | <1% | 5,527 | $50K | |
| 90680 | <1% | 5,395 | $49K | |
| 74246 | <1% | 351 | $48K | |
| 87634 | <1% | 736 | $48K | |
| 72110 | <1% | 1,230 | $47K | |
| 74018 | <1% | 1,776 | $44K | |
| 62321 | <1% | 167 | $44K | |
| 86900 | <1% | 4,905 | $43K | |
| D1206 | Topical application of fluoride varnish | <1% | 2,157 | $42K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,489 | $42K |
| 88342 | <1% | 2,667 | $41K | |
| 90723 | <1% | 4,548 | $41K | |
| 76536 | <1% | 535 | $40K | |
| 84702 | <1% | 2,806 | $40K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,966 | $40K |
| 72141 | <1% | 170 | $40K | |
| 73140 | <1% | 2,153 | $39K | |
| 90647 | <1% | 4,319 | $39K | |
| 87040 | <1% | 3,294 | $38K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 43 | $38K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 479 | $37K |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 1,094 | $36K |
| 59430 | <1% | 484 | $36K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,912 | $35K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 577 | $34K |
| 92551 | <1% | 23,093 | $33K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 980 | $33K |
| 82607 | <1% | 2,552 | $32K | |
| 81001 | <1% | 10,885 | $32K | |
| 81003 | <1% | 15,046 | $32K | |
| 73590 | <1% | 1,429 | $31K | |
| 87486 | <1% | 864 | $31K | |
| 87581 | <1% | 868 | $31K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,164 | $31K |
| 20610 | <1% | 1,155 | $30K | |
| 31231 | <1% | 505 | $30K | |
| 90651 | <1% | 2,905 | $30K | |
| 11102 | <1% | 297 | $30K | |
| 84460 | <1% | 8,296 | $30K | |
| 82247 | <1% | 8,147 | $30K | |
| 95251 | <1% | 871 | $29K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 52 | $29K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 604 | $29K |
| 82948 | <1% | 2,943 | $29K | |
| 73560 | <1% | 1,487 | $29K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,186 | $29K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,290 | $28K |
| 84450 | <1% | 8,160 | $28K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 357 | $28K |
| 80074 | <1% | 692 | $27K | |
| 83735 | <1% | 6,245 | $27K | |
| 82728 | <1% | 1,732 | $27K | |
| 31237 | <1% | 284 | $27K | |
| 86803 | <1% | 2,172 | $27K | |
| V2632 | Posterior chamber intraocular lens | <1% | 286 | $26K |
| 87481 | <1% | 254 | $26K | |
| 86140 | <1% | 5,986 | $25K | |
| 0160 | <1% | 678 | $25K | |
| 84075 | <1% | 7,880 | $25K | |
| 83880 | <1% | 1,435 | $25K | |
| 72050 | <1% | 723 | $25K | |
| 81015 | <1% | 9,919 | $25K | |
| 83605 | <1% | 3,025 | $24K | |
| 95115 | <1% | 3,640 | $23K | |
| 86780 | <1% | 2,080 | $23K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,719 | $23K |
| 90697 | <1% | 2,552 | $23K | |
| 85610 | <1% | 8,122 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,352 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,169 | $22K |
| 98926 | <1% | 509 | $22K | |
| 90698 | <1% | 2,462 | $22K | |
| 90734 | <1% | 2,194 | $21K | |
| 81513 | <1% | 129 | $21K | |
| 84153 | <1% | 1,238 | $21K | |
| 85730 | <1% | 4,486 | $21K | |
| 76870 | <1% | 310 | $20K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 682 | $20K |
| 87510 | <1% | 1,159 | $20K | |
| 87480 | <1% | 1,159 | $20K | |
| 31575 | <1% | 255 | $20K | |
| 87660 | <1% | 1,145 | $20K | |
| 84155 | <1% | 8,050 | $20K | |
| 87340 | <1% | 2,107 | $19K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,691 | $19K |
| 73090 | <1% | 813 | $19K | |
| 82043 | <1% | 3,594 | $19K | |
| 99223 | Prolong inpt eval add15 m | <1% | 121 | $19K |
| 99401 | <1% | 1,478 | $18K | |
| 86480 | <1% | 357 | $18K | |
| 90681 | <1% | 1,978 | $18K | |
| Z1032 | <1% | 89 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,205 | $17K |
| 99241 | <1% | 494 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,345 | $17K |
| 82570 | <1% | 3,550 | $17K | |
| 71250 | <1% | 127 | $17K | |
| Z6400 | <1% | 970 | $17K | |
| 52000 | <1% | 169 | $17K | |
| 72040 | <1% | 638 | $17K | |
| 88142 | <1% | 3,715 | $17K | |
| 84439 | <1% | 2,039 | $16K | |
| 64615 | <1% | 141 | $16K | |
| 86762 | <1% | 1,215 | $16K | |
| 80069 | <1% | 4,054 | $15K | |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | <1% | 39 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,736 | $15K |
| 84481 | <1% | 1,056 | $15K | |
| 64493 | <1% | 98 | $15K | |
| 93017 | <1% | 328 | $15K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 256 | $15K |
| H2000 | Comprehensive multidisciplinary evaluation | <1% | 88 | $15K |
| 88313 | <1% | 1,349 | $15K | |
| 51701 | <1% | 138 | $15K | |
| 99173 | <1% | 5,447 | $14K | |
| 84403 | <1% | 650 | $14K | |
| 76000 | <1% | 341 | $14K | |
| 96156 | <1% | 1,177 | $14K | |
| 87070 | <1% | 1,896 | $14K | |
| 90744 | <1% | 1,597 | $14K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 4,578 | $14K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,177 | $14K |
| 82947 | <1% | 4,714 | $14K | |
| 72114 | <1% | 246 | $13K | |
| 82746 | <1% | 994 | $13K | |
| 82652 | <1% | 591 | $13K | |
| 72072 | <1% | 440 | $13K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 89 | $13K |
| 70496 | <1% | 51 | $13K | |
| 86701 | <1% | 1,666 | $13K | |
| 86901 | <1% | 4,861 | $13K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,619 | $13K |
| 94060 | <1% | 251 | $12K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 5,422 | $12K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 284 | $12K |
| 97597 | <1% | 309 | $12K | |
| 90710 | <1% | 1,295 | $12K | |
| 90700 | <1% | 1,320 | $12K | |
| 31579 | <1% | 69 | $12K | |
| 85379 | <1% | 1,334 | $12K | |
| 80076 | <1% | 1,973 | $12K | |
| 10060 | <1% | 240 | $11K | |
| 51784 | <1% | 282 | $11K | |
| 0420 | <1% | 201 | $11K | |
| 85651 | <1% | 4,876 | $11K | |
| 90696 | <1% | 1,199 | $11K | |
| 88307 | <1% | 402 | $11K | |
| 90716 | <1% | 1,175 | $11K | |
| 90677 | <1% | 766 | $11K | |
| 97803 | <1% | 851 | $11K | |
| 84480 | <1% | 703 | $11K | |
| 83655 | <1% | 1,548 | $11K | |
| 90707 | <1% | 1,185 | $11K | |
| 90648 | <1% | 1,167 | $11K | |
| 94760 | <1% | 1,849 | $10K | |
| 0011A | <1% | 268 | $10K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 943 | $10K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 198 | $10K |
| 83550 | <1% | 1,175 | $10K | |
| G9012 | Other specified case management service not elsewhere classified | <1% | 830 | $10K |
| 87430 | <1% | 1,296 | $10K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 150 | $10K |
| 93325 | <1% | 91 | $10K | |
| 86787 | <1% | 803 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 681 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,642 | $9K |
| 83540 | <1% | 1,528 | $9K | |
| 85007 | <1% | 3,396 | $9K | |
| 0012A | <1% | 222 | $9K | |
| 83001 | <1% | 551 | $9K | |
| 82550 | <1% | 1,533 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,329 | $9K |
| J1815 | Injection, insulin, per 5 units | <1% | 285 | $9K |
| 99358 | Prolong nursin fac eval 15m | <1% | 253 | $8K |
| 84146 | <1% | 489 | $8K | |
| 90649 | <1% | 689 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,691 | $8K |
| 99442 | <1% | 154 | $8K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 51 | $8K |
| 99407 | <1% | 379 | $8K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 221 | $8K |
| 0259 | <1% | 2,834 | $8K | |
| 87081 | <1% | 1,128 | $8K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 99 | $7K |
| 76942 | <1% | 254 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,580 | $7K |
| 95910 | <1% | 41 | $7K | |
| 0272 | <1% | 870 | $7K | |
| Z6410 | <1% | 473 | $7K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,428 | $7K |
| 70498 | <1% | 36 | $7K | |
| 51741 | <1% | 547 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,281 | $7K |
| 82785 | <1% | 847 | $7K | |
| 83014 | <1% | 763 | $6K | |
| C1781 | Mesh (implantable) | <1% | 25 | $6K |
| 93320 | <1% | 104 | $6K | |
| 83516 | <1% | 407 | $6K | |
| 73660 | <1% | 389 | $6K | |
| 27096 | <1% | 27 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 436 | $6K |
| 99205 | Prolong outpt/office vis | <1% | 53 | $6K |
| 95909 | <1% | 52 | $6K | |
| 11981 | <1% | 28 | $6K | |
| 84425 | <1% | 356 | $5K | |
| 86706 | <1% | 583 | $5K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 118 | $5K |
| 94729 | <1% | 87 | $5K | |
| 64494 | <1% | 69 | $5K | |
| 29125 | <1% | 93 | $5K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 434 | $5K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 281 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 222 | $5K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 668 | $5K |
| 74247 | <1% | 28 | $5K | |
| 86038 | <1% | 890 | $5K | |
| 95908 | <1% | 43 | $5K | |
| 93000 | <1% | 127 | $5K | |
| 83002 | <1% | 288 | $5K | |
| 73020 | <1% | 274 | $4K | |
| 86403 | <1% | 491 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 870 | $4K |
| 99383 | <1% | 61 | $4K | |
| 82950 | <1% | 946 | $4K | |
| 82565 | <1% | 456 | $4K | |
| 11100 | <1% | 104 | $4K | |
| 71101 | <1% | 134 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 107 | $4K |
| 99406 | <1% | 308 | $4K | |
| 90671 | <1% | 403 | $4K | |
| 64495 | <1% | 49 | $4K | |
| 12011 | <1% | 42 | $4K | |
| 11976 | <1% | 56 | $4K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 585 | $4K |
| 86235 | <1% | 105 | $3K | |
| 94726 | <1% | 58 | $3K | |
| 82962 | <1% | 1,790 | $3K | |
| 83883 | <1% | 150 | $3K | |
| 95912 | <1% | 12 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,021 | $3K |
| Z7610 | <1% | 948 | $3K | |
| 87420 | <1% | 789 | $3K | |
| 86580 | <1% | 736 | $3K | |
| 94664 | <1% | 205 | $3K | |
| 76937 | <1% | 137 | $3K | |
| 82670 | <1% | 125 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 561 | $3K |
| 96127 | <1% | 505 | $3K | |
| 88112 | <1% | 84 | $3K | |
| 99381 | <1% | 24 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 458 | $3K |
| 86704 | <1% | 266 | $3K | |
| 83970 | <1% | 96 | $3K | |
| 98925 | <1% | 96 | $3K | |
| 86431 | <1% | 668 | $3K | |
| 90750 | <1% | 13 | $2K | |
| 11103 | <1% | 19 | $2K | |
| 90620 | <1% | 268 | $2K | |
| 88312 | <1% | 288 | $2K | |
| H1002 | Prenatal care, at risk enhanced service; care coordination | <1% | 14 | $2K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 342 | $2K |
| 87205 | <1% | 736 | $2K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 27 | $2K |
| 99384 | <1% | 27 | $2K | |
| 0270 | <1% | 2,184 | $2K | |
| 99152 | <1% | 53 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 403 | $2K |
| 43235 | <1% | 24 | $2K | |
| 83615 | <1% | 511 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 448 | $2K |
| 86039 | <1% | 282 | $2K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 151 | $2K |
| 90685 | <1% | 192 | $2K | |
| 86592 | <1% | 260 | $2K | |
| 73100 | <1% | 97 | $2K | |
| 87799 | <1% | 14 | $2K | |
| 86696 | <1% | 303 | $2K | |
| 90656 | <1% | 175 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 71 | $2K |
| 86255 | <1% | 101 | $2K | |
| 86160 | <1% | 106 | $2K | |
| 17000 | <1% | 27 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 244 | $2K |
| 0071A | <1% | 37 | $1K | |
| 51729 | <1% | 12 | $1K | |
| 82465 | <1% | 477 | $1K | |
| 96151 | <1% | 137 | $1K | |
| 82784 | <1% | 187 | $1K | |
| 90732 | <1% | 65 | $1K | |
| 99426 | <1% | 25 | $1K | |
| 86765 | <1% | 115 | $1K | |
| 84145 | <1% | 93 | $1K | |
| 73620 | <1% | 71 | $1K | |
| 57454 | <1% | 12 | $1K | |
| 85014 | <1% | 587 | $1K | |
| G9920 | Screening performed and negative | <1% | 2,512 | $1K |
| 82977 | <1% | 169 | $1K | |
| 84402 | <1% | 81 | $1K | |
| 86376 | <1% | 112 | $1K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 194 | $1K |
| 86735 | <1% | 94 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 73 | $1K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 62 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 212 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 219 | $1K |
| 87512 | <1% | 25 | $953.20 | |
| 12001 | <1% | 14 | $929.52 | |
| 73070 | <1% | 44 | $910.81 | |
| 11900 | <1% | 39 | $907.33 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 82 | $907.07 |
| 86328 | <1% | 28 | $885.21 | |
| 74019 | <1% | 38 | $852.29 | |
| 0636 | <1% | 1,066 | $848.92 | |
| 96158 | <1% | 76 | $840.88 | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | <1% | 543 | $828.85 |
| 58301 | <1% | 23 | $795.21 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 242 | $794.88 |
| 82805 | <1% | 27 | $794.54 | |
| 86200 | <1% | 117 | $790.02 | |
| 82150 | <1% | 154 | $778.55 | |
| 82140 | <1% | 59 | $772.62 | |
| 73000 | <1% | 29 | $758.35 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 38 | $743.45 |
| 73600 | <1% | 39 | $718.42 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 112 | $690.22 |
| 0004A | <1% | 16 | $640.00 | |
| 0124A | <1% | 15 | $600.00 | |
| 0001A | <1% | 15 | $600.00 | |
| 73060 | <1% | 36 | $593.70 | |
| 82803 | <1% | 77 | $590.41 | |
| 0064A | <1% | 13 | $520.00 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 71 | $504.51 |
| 87147 | <1% | 130 | $504.14 | |
| 11721 | <1% | 12 | $493.32 | |
| 72170 | <1% | 14 | $491.96 | |
| 98960 | <1% | 15 | $479.85 | |
| 87338 | <1% | 40 | $479.18 | |
| 99459 | <1% | 30 | $468.56 | |
| 84270 | <1% | 44 | $455.17 | |
| 77002 | <1% | 17 | $412.33 | |
| 85652 | <1% | 104 | $387.72 | |
| 90713 | <1% | 42 | $378.00 | |
| 90658 | <1% | 14 | $372.12 | |
| 86225 | <1% | 44 | $366.30 | |
| 86695 | <1% | 53 | $334.85 | |
| 82248 | <1% | 60 | $329.96 | |
| 86308 | <1% | 77 | $326.78 | |
| 82105 | <1% | 27 | $302.64 | |
| 51797 | <1% | 12 | $298.34 | |
| 99201 | <1% | 13 | $295.62 | |
| 96150 | <1% | 13 | $273.52 | |
| 82172 | <1% | 17 | $272.68 | |
| 93312 | <1% | 13 | $272.60 | |
| 90480 | <1% | 14 | $267.50 | |
| Z6406 | <1% | 15 | $265.39 | |
| S9452 | Nutrition classes, non-physician provider, per session | <1% | 25 | $262.75 |
| 74021 | <1% | 12 | $247.08 | |
| 87807 | <1% | 27 | $243.32 | |
| 86708 | <1% | 24 | $241.78 | |
| 83010 | <1% | 18 | $236.72 | |
| 86709 | <1% | 25 | $232.08 | |
| 82951 | <1% | 12 | $231.82 | |
| 73120 | <1% | 16 | $227.33 | |
| 82274 | <1% | 13 | $226.59 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 44 | $215.93 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 38 | $198.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 45 | $182.02 |
| 86694 | <1% | 16 | $162.56 | |
| 87210 | <1% | 52 | $158.90 | |
| 76882 | <1% | 13 | $155.71 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 94 | $154.57 |
| A4217 | Sterile water/saline, 500 ml | <1% | 25 | $149.97 |
| 82533 | <1% | 12 | $142.30 | |
| 95117 | <1% | 12 | $141.72 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 85 | $140.13 |
| 84520 | <1% | 44 | $131.80 | |
| 90619 | <1% | 14 | $126.00 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 23 | $115.66 |
| 82390 | <1% | 12 | $111.84 | |
| 90733 | <1% | 12 | $108.00 | |
| 87177 | <1% | 12 | $93.96 | |
| 88302 | <1% | 12 | $91.98 | |
| 84436 | <1% | 15 | $82.32 | |
| 82952 | <1% | 12 | $71.21 | |
| 86021 | <1% | 12 | $62.78 | |
| 84100 | <1% | 26 | $61.65 | |
| 97116 | <1% | 20 | $59.22 | |
| 82270 | <1% | 16 | $51.31 | |
| 85347 | <1% | 15 | $48.08 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 86 | $47.55 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $46.03 |
| 88311 | <1% | 27 | $34.74 | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 58 | $29.57 |
| 0370 | <1% | 608 | $21.55 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 19 | $20.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 111 | $11.28 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $7.53 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 120 | $6.76 |
| 0637 | <1% | 710 | $6.37 | |
| 90662 | 0% | 16 | $0.00 | |
| 1036F | 0% | 240 | $0.00 | |
| G0467 | Community health center visit, returning patient | 0% | 484 | $0.00 |
| C1769 | Guide wire | 0% | 174 | $0.00 |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 96 | $0.00 |
| 1000F | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZDEBLICK, MICHAEL (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Community Memorial Health System | Ojai, CA | $2.12M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.